IXCHIQ

About IXCHIQ

IXCHIQ is the world’s first and only licensed chikungunya vaccine available to address this significant unmet medical need. The vaccine is currently approved in the U.S.[1], Europe[2], and Canada[3] for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older. The U.S. launch is underway while first sales in Canada and Europe are anticipated in the fourth quarter of 2024.

Schedule

Single dose.

Side Effects

Well tolerated; occasional headache, myalgia, fatigue, and fever.

We monitor the world for travel disruptions or threatening events and notify you so you don't run into anything unexpected

Learn more